Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667873 · ClinicalTrials.gov registry record · Phase 1
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Stemline Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02667873 is a Phase 1 study that has completed, run by Stemline Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT02667873, a Phase 1 study, has completed, sponsored by Stemline Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.
Interventions
- DRUG SL-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2021-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667873
The ClinicalTrials.gov registry entry for NCT02667873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SL-801 is the first listed.
NCT02667873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02667873 about?
NCT02667873 is a clinical study titled "A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors". Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.
What is the current status of trial NCT02667873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-02-23. Estimated completion is 2021-10-13.
What interventions are being tested in trial NCT02667873?
The interventions under investigation include: SL-801 (DRUG).
Who is sponsoring clinical trial NCT02667873?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.